Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
Shanghai Chest Hospital
M.D. Anderson Cancer Center
Second Affiliated Hospital of Nanchang University
Georgetown University
Tianjin Medical University Cancer Institute and Hospital
City of Hope Medical Center
Fundación GECP
Shanghai Pulmonary Hospital, Shanghai, China
Sun Yat-sen University
Ruijin Hospital
University of Rochester
Hunan Province Tumor Hospital
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou Medical University
Lebanese University
N.N. Petrov National Medical Research Center of Oncology
M.D. Anderson Cancer Center
University of California, San Francisco
Intergroupe Francophone de Cancerologie Thoracique
Cambridge University Hospitals NHS Foundation Trust
Rutgers, The State University of New Jersey
Case Comprehensive Cancer Center
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Guangdong Association of Clinical Trials
Barbara Ann Karmanos Cancer Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University
M.D. Anderson Cancer Center
University Hospital Regensburg
Northwestern University
Swiss Cancer Institute
Swiss Cancer Institute
M.D. Anderson Cancer Center
Barbara Ann Karmanos Cancer Institute
University of Massachusetts, Worcester
M.D. Anderson Cancer Center
Holy Cross Hospital, Florida
Masonic Cancer Center, University of Minnesota
UNC Lineberger Comprehensive Cancer Center
University of Alabama at Birmingham
UNC Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Rutgers, The State University of New Jersey
Stanford University
Alliance for Clinical Trials in Oncology
Stanford University
SCRI Development Innovations, LLC
Alliance for Clinical Trials in Oncology
University of Cologne